{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T04:34:08Z","timestamp":1760243648471,"version":"build-2065373602"},"reference-count":28,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2022,8,29]],"date-time":"2022-08-29T00:00:00Z","timestamp":1661731200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Xijing Hospital discipline boost","award":["XJZT18MDT18","81872265"],"award-info":[{"award-number":["XJZT18MDT18","81872265"]}]},{"name":"Multidisciplinary comprehensive diagnosis and treatment project (key project)","award":["XJZT18MDT18","81872265"],"award-info":[{"award-number":["XJZT18MDT18","81872265"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["XJZT18MDT18","81872265"],"award-info":[{"award-number":["XJZT18MDT18","81872265"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Oncology"],"abstract":"<jats:p>Durvalumab consolidation therapy is the standard treatment after concurrent chemoradiotherapy for patients with surgically unresectable stage IIIA (N2) non-small-cell lung cancer (NSCLC). Neoadjuvant therapy followed by surgery could reduce locoregional and distant recurrence and improve the survival rate for surgically resectable NSCLC. However, the value of neoadjuvant therapy in locally advanced potentially resectable NSCLC remains controversial. Herein, we report a locally advanced potentially resectable NSCLC case with a history of breast cancer who achieved a pathologic complete response (pCR) after preoperative treatment with pembrolizumab and chemotherapy. A 50-year-old woman developed squamous cell carcinoma (SCC) (left lower lobe of the lung, stage IIIA-N2) after two years of chemotherapy and anti-HER2 therapy following a diagnosis of HER2-overexpressing breast cancer. Surgical resection was attempted despite an MDT classification as unamenable to curative surgical resection. After two cycles of neoadjuvant chemotherapy combined with anti-PD1 immunotherapy, the tumor significantly shrank, then the patient underwent a left lower lobectomy. Complete resection with negative margins (R0 resection) was achieved in the patient. The patient experienced grade 1\u20132 adverse effects and no grade 3 or worse adverse effects occurred. Cardiotoxicity did not occur in the patient despite prior anti-HER2 treatment for breast cancer. Our case study contributes to the existing evidence on the feasibility, efficacy, and safety of neoadjuvant immunotherapy combined with chemotherapy in locally advanced unresectable NSCLC. Furthermore, future studies are needed to determine which patients can benefit from immunoadjuvant therapy and the duration and course of preoperative and postoperative immunotherapy.<\/jats:p>","DOI":"10.3390\/curroncol29090487","type":"journal-article","created":{"date-parts":[[2022,8,29]],"date-time":"2022-08-29T21:01:31Z","timestamp":1661806891000},"page":"6203-6210","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Neoadjuvant Immunotherapy Combined with Chemotherapy for Local Advanced Non-Small-Cell Lung Cancer in a Patient with a History of Breast Cancer: A Case Report"],"prefix":"10.3390","volume":"29","author":[{"given":"Rui-Xia","family":"Yang","sequence":"first","affiliation":[{"name":"Department of Oncology, Xijing Hospital of Air Force Military Medical University, Xi\u2019an 710032, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yue","family":"Hei","sequence":"additional","affiliation":[{"name":"Department of Oncology, Xijing Hospital of Air Force Military Medical University, Xi\u2019an 710032, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wen-Ting","family":"Zhu","sequence":"additional","affiliation":[{"name":"Department of Oncology, Xijing Hospital of Air Force Military Medical University, Xi\u2019an 710032, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qian-Rong","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Oncology, Xijing Hospital of Air Force Military Medical University, Xi\u2019an 710032, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3991-3750","authenticated-orcid":false,"given":"Hong-Mei","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Oncology, Xijing Hospital of Air Force Military Medical University, Xi\u2019an 710032, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Oncology, Xijing Hospital of Air Force Military Medical University, Xi\u2019an 710032, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2022,8,29]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"394","DOI":"10.3322\/caac.21492","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J. Clin."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1200\/JCO.2009.26.2543","article-title":"Meta-Analysis of Concomitant Versus Sequential Radiochemotherapy in Locally Advanced Non\u2013Small-Cell Lung Cancer","volume":"28","author":"Rolland","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"NSCLC Meta-analysis Collaborative Group (2014). Preoperative chemotherapy for non-small-cell lung cancer: A systematic review and meta-analysis of individual participant data. Lancet, 383, 1561\u20131571.","DOI":"10.1016\/S0140-6736(13)62159-5"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.21873\/invivo.11605","article-title":"Breast Cancer and Multiple Primary Malignant Tumors: Case Report and Review of the Literature","volume":"33","author":"Frusone","year":"2019","journal-title":"Vivo"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1038\/s41417-019-0084-z","article-title":"Clinical characteristics and prognostic analysis of multiple primary malignant neoplasms in patients with lung cancer","volume":"26","author":"Wang","year":"2019","journal-title":"Cancer Gene Ther."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.3349\/ymj.2015.56.5.1213","article-title":"Characteristics and Survival of Breast Cancer Patients with Multiple Synchronous or Metachronous Primary Cancers","volume":"56","author":"Lee","year":"2015","journal-title":"Yonsei Med. J."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.radonc.2018.05.032","article-title":"Long-term risks of secondary cancer for various whole and partial breast irradiation techniques","volume":"128","author":"Hoekstra","year":"2018","journal-title":"Radiother. Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1200\/JCO.2016.72.0722","article-title":"Estimating the Risks of Breast Cancer Radiotherapy: Evidence From Modern Radiation Doses to the Lungs and Heart and From Previous Randomized Trials","volume":"35","author":"Taylor","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"713328","DOI":"10.3389\/fonc.2021.713328","article-title":"Estimation of Annual Secondary Lung Cancer Deaths Using Various Adjuvant Breast Radiotherapy Techniques for Early-Stage Cancers","volume":"11","author":"Pignol","year":"2021","journal-title":"Front. Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Mielgo-Rubio, X., Montemui\u00f1o, S., Jim\u00e9nez, U., Luna, J., Carde\u00f1a, A., Mezquita, L., Mart\u00edn, M., and Cou\u00f1ago, F. (2021). Management of Resectable Stage III-N2 Non-Small-Cell Lung Cancer (NSCLC) in the Age of Immunotherapy. Cancers, 13.","DOI":"10.3390\/cancers13194811"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.jtho.2019.10.022","article-title":"Asian Thoracic Oncology Research Group Expert Consensus Statement on Optimal Management of Stage III NSCLC","volume":"15","author":"Tan","year":"2020","journal-title":"J. Thorac. Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.jtho.2015.09.009","article-title":"The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer","volume":"11","author":"Goldstraw","year":"2016","journal-title":"J. Thorac. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1016\/S0140-6736(15)60294-X","article-title":"Induction chemoradiation in stage IIIA\/N2 non-small-cell lung cancer: A phase 3 randomised trial","volume":"386","author":"Pless","year":"2015","journal-title":"Lancet"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"3138","DOI":"10.1200\/JCO.2009.27.6204","article-title":"Preoperative Chemotherapy Plus Surgery Versus Surgery Plus Adjuvant Chemotherapy Versus Surgery Alone in Early-Stage Non\u2013Small-Cell Lung Cancer","volume":"28","author":"Felip","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1200\/JCO.2010.33.7089","article-title":"Randomized Phase III Study of Surgery Alone or Surgery Plus Preoperative Cisplatin and Gemcitabine in Stages IB to IIIA Non\u2013Small-Cell Lung Cancer","volume":"30","author":"Scagliotti","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.drup.2017.07.002","article-title":"Immunotherapy for triple-negative breast cancer: Existing challenges and exciting prospects","volume":"32","author":"Jia","year":"2017","journal-title":"Drug Resist. Updat."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1016\/j.jtho.2018.09.017","article-title":"Current Status and Future Perspectives on Neoadjuvant Therapy in Lung Cancer","volume":"13","author":"Blumenthal","year":"2018","journal-title":"J. Thorac. Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"8503","DOI":"10.1200\/JCO.2021.39.15_suppl.8503","article-title":"Surgical outcomes from the phase 3 CheckMate 816 trial: Nivolumab (NIVO) + platinum-doublet chemotherapy (chemo) vs chemo alone as neoadjuvant treatment for patients with resectable non-small cell lung cancer (NSCLC)","volume":"39","author":"Spicer","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/j.jtho.2020.01.017","article-title":"Neoadjuvant PD-1 inhibitor (Sintilimab) in NSCLC","volume":"15","author":"Gao","year":"2020","journal-title":"J. Thorac. Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/nature14011","article-title":"Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients","volume":"515","author":"Herbst","year":"2014","journal-title":"Nature"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1126\/science.aaa1348","article-title":"Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non\u2013small cell lung cancer","volume":"348","author":"Rizvi","year":"2015","journal-title":"Science"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"3012","DOI":"10.1158\/1078-0432.CCR-16-2554","article-title":"Potential Predictive Value of TP53 and KRAS Mutation Status for Response to PD-1 Blockade Immunotherapy in Lung Adenocarcinoma","volume":"23","author":"Dong","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"5710","DOI":"10.1158\/1078-0432.CCR-18-0163","article-title":"TP53, STK11, and EGFR Mutations Predict Tumor Immune Profile and the Response to Anti\u2013PD-1 in Lung Adenocarcinoma","volume":"24","author":"Biton","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1007\/s40259-020-00425-y","article-title":"Pseudoprogression and Hyperprogression as New Forms of Response to Immunotherapy","volume":"34","author":"Frelaut","year":"2020","journal-title":"BioDrugs"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1158\/1078-0432.CCR-16-1741","article-title":"Hyperprogressive Disease Is a New Pattern of Progression in Cancer Patients Treated by Anti-PD-1\/PD-L1","volume":"23","author":"Champiat","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.lungcan.2018.08.012","article-title":"Change in the lymphocyte-to-monocyte ratio is an early surrogate marker of the efficacy of nivolumab monotherapy in advanced non-small-cell lung cancer","volume":"124","author":"Sekine","year":"2018","journal-title":"Lung Cancer"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1007\/s00262-021-03071-7","article-title":"Assessment of immune status of laryngeal squamous cell carcinoma can predict prognosis and guide treatment","volume":"71","author":"Wang","year":"2021","journal-title":"Cancer Immunol. Immunother."}],"container-title":["Current Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1718-7729\/29\/9\/487\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T00:19:21Z","timestamp":1760141961000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1718-7729\/29\/9\/487"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,29]]},"references-count":28,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2022,9]]}},"alternative-id":["curroncol29090487"],"URL":"https:\/\/doi.org\/10.3390\/curroncol29090487","relation":{},"ISSN":["1718-7729"],"issn-type":[{"type":"electronic","value":"1718-7729"}],"subject":[],"published":{"date-parts":[[2022,8,29]]}}}